Overview

Detailed Summary

Alivus Life Sciences Limited, formerly Glenmark Life Sciences, specializes in developing, manufacturing, and marketing Active Pharmaceutical Ingredients (APIs) across various therapeutic segments.
The company's Q3 FY26 revenue saw substantial growth of 14.4% QoQ, driven by recovery in the CDMO segment and robust demand in regulated markets such as Europe and Japan.
Alivus has successfully expanded its capacity, notably in Dahej and Ankleshwar, aligning with its strategy of supporting sustained growth in its CDMO and API businesses.
The company reported its highest ever EBITDA margin of 36.4% in Q3 FY26, supported by new product launches and favorable product mixes.
Alivus is strategically focused on expanding its CDMO business, aiming for new project wins and leveraging operational efficiencies to sustain margin expansion.

Sector: Pharmaceuticals & Biotechnology
Industry: Pharmaceuticals
Market Cap: 13,534 Cr
Volatility: Low Risk
P/E Ratio: 24.0
Industry P/E: 37.2
PEG Ratio: 1.9
P/B Ratio: 4.2
52W High: 1,193.30
52W Low: 830.00

Sales CAGR

1Y: 4.54%
3Y: 3.98%
5Y: 9.20%
10Y: —

Profit CAGR

1Y: 3.13%
3Y: 5.07%
5Y: 9.18%
10Y: —

ROE

TTM: 16.94%
3Y: 19.53%
5Y: 21.73%
10Y: —

ROCE

TTM: 22.33%
3Y: 25.38%
5Y: 29.46%
10Y: —

Technicals

‌

Forecasts

Unlock more with professional

Analyst Target, Price, EPS and Revenue Projections
Get In-depth insights on EPS and Revenue forecasts

Peers

Healthcare Healthcare Pharmaceuticals

Symbol	Watchlist	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
APLLTD		814.90	16,009 Cr	23.73	2.82	1.47	11.89	10.81	7.66
JUBLPHARMA		975.00	15,584 Cr	39.11	2.20	0.51	5.62	6.41	2.56
ALIVUS		1134.25	13,876 Cr	24.58	4.16	0.44	16.94	22.33	14.17
CONCORDBIO		1260.00	13,150 Cr	50.40	6.52	0.60	12.94	17.08	11.60
CORONA		2101.90	12,807 Cr	69.18	17.15	0.48	24.79	27.13	15.36
SHILPAMED		623.95	12,144 Cr	49.91	4.69	0.10	9.39	10.73	6.57
MARKSANS		263.00	11,941 Cr	28.57	3.95	0.34	13.82	17.37	10.88
Median: 7 Co.	—	975.00	13,150 Cr	39.11	4.16	0.48	12.94	17.08	10.88

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Standalone Quarterly Results (in ₹ Crores)

Total Figures

QoQ Changes

Total Figures

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Sales	573	537	589	507	642	650	602	588	673	689
Expenses	400	395	429	373	452	451	430	409	442	475
Operating Profit	173	141	159	134	190	198	172	179	231	215
OPM %	30.12	26.36	27.10	26.51	29.65	30.55	28.63	30.47	34.37	31.13
Other Income	1.69	3.13	5.49	8.53	10	10	8.99	15	-12	23
Interest	0.39	0.36	0.35	0.34	0.46	1.26	1.25	1.32	1.49	1.31
Depreciation	13	15	14	15	15	16	17	18	20	20
Profit Before Tax	161	130	150	127	185	191	163	174	198	216
Tax %	26.09	24.48	25.80	25.22	26.03	25.84	25.43	25.33	24.26	24.62
Net Profit	119	98	111	95	137	142	122	130	150	163
EPS in Rs	9.65	7.96	9.06	7.74	11.12	11.53	9.87	10.59	12.21	13.22

Standalone Profit Loss (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Sales	0.25	886	1,537	1,885	2,123	2,161	2,283	2,387	2,400
Expenses	0.26	639	1,065	1,294	1,507	1,519	1,609	1,704	1,705
Operating Profit	-0.01	248	472	591	616	642	674	683	695
OPM %	-5.24	27.95	30.70	31.35	29.02	29.72	29.53	28.60	28.97
Other Income	0.00	0.44	12	0.81	15	29	12	35	38
Interest	0.00	0.61	34	88	28	0.55	1.55	2.41	3.31
Depreciation	0.00	19	29	33	38	42	53	61	63
Profit Before Tax	-0.01	228	421	471	565	629	631	654	667
Tax %	-3,238.46	14.33	25.64	25.35	25.88	25.72	25.41	25.76	25.67
Net Profit	-0.43	196	313	352	419	467	471	486	496
EPS in Rs	—	—	—	32.61	35.90	38.03	38.31	39.45	45.90
Dividend Payout %	0.00	0.00	0.00	0.00	58.94	110.21	58.62	12.65	—

Standalone Balance Sheet (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	0.01	1.96	1.96	1.96	25	25	25	25
Reserves	-1.41	86	400	751	2,030	2,114	2,308	2,793
Borrowings	0.00	0.02	0.02	0.00	2.88	19	17	57
Other Liabilities	1.48	1,387	1,324	1,244	414	545	501	537
Total Liabilities	0.09	1,475	1,726	1,997	2,471	2,702	2,850	3,411
Fixed Assets	0.00	456	546	573	590	781	805	955
CWIP	0.00	80	11	14	97	62	106	102
Investments	0.00	0.08	0.08	0.08	0.08	0.08	0.08	478
Other Assets	0.08	939	1,169	1,410	1,784	1,860	1,939	1,877
Total Assets	0.09	1,475	1,726	1,997	2,471	2,702	2,850	3,411

Standalone Cash Flows (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	-0.48	10	195	388	598	306	414	392
Cash from Investing Activity	0.00	-8.83	-51	-69	-122	-147	-116	-616
Cash from Financing Activity	0.49	0.54	-137	-214	-79	-388	-279	-6.23
Net Cash Flow	0.01	2.05	7.94	106	397	-228	18	-230

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	82.85%	82.85%	82.85%	82.85%	75.00%	75.00%	74.99%	74.94%	74.91%	74.91%	74.87%	74.87%
FIIs	4.38%	4.57%	5.01%	4.82%	7.85%	6.74%	6.57%	6.42%	6.84%	5.09%	5.29%	5.54%
DIIs	0.64%	0.74%	1.40%	1.57%	4.16%	4.86%	5.19%	5.61%	5.47%	7.12%	7.28%	7.18%
Public	12.12%	11.84%	10.73%	10.76%	12.98%	13.40%	13.25%	13.03%	12.78%	12.88%	12.56%	12.41%
Total Shareholders	1,98,764	1,85,531	1,56,183	1,49,396	1,43,960	1,46,840	1,41,977	1,38,500	1,35,643	1,32,748	1,27,969	1,25,559

Market Transactions

Unlock more with professional

Real-time bulk & block deal transactions
Export transaction data for analysis

Projection

Unlock more with professional

Analyst Target, Price, EPS and Revenue Projections
Get In-depth insights on EPS and Revenue forecasts

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q4 FY26

Investor Presentation

Q3 FY26

Investor Presentation

Q2 FY26

Investor Presentation

Q1 FY26

Investor Presentation

Q3 FY25

Investor Presentation

Q2 FY25

Investor Presentation

Q1 FY25

Investor Presentation

Q4 FY24

Showing 1 - 8 of 21

Actions

Action Type

‌
‌

Announcements

Last 7 days

Sentiment

Earnings Call/Transcript

4 days ago

Alivus Life Sciences Q1 FY2026-27 Earnings Call

Alivus Life Sciences Ltd: Q1 FY2026-27 earnings call scheduled on 2026-07-31 from 08:30 to 09:30 IST; dial-in numbers and preregistration link provided for investors.

Earnings Call/Transcript

4 days ago

Alivus Life Sciences Q1 FY2026-27 Earnings Call

Alivus Life Sciences announces Q1 FY2026-27 earnings call on July 31, 2026 from 08:30 to 09:30 IST; dial-in numbers, international toll-free lines and online pre-registration link provided.

Board Meeting

5 days ago

Alivus Life Sciences Board Meeting on July 30, 2026

Alivus Life Sciences Ltd: Board meeting scheduled for 2026-07-30 to consider and approve unaudited financial results for quarter ended 30-06-2026. Trading window closed from 2026-07-01 to 2026-08-01.

Board Meeting

5 days ago

Alivus Life Sciences Board Meeting July 30, 2026

Alivus Life Sciences Ltd will hold a Board meeting on 2026-07-30 to consider and approve unaudited financial results for the quarter ended 2026-06-30. Trading window closed from 2026-07-01 to 2026-08-01 (inclusive).

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

Ask AI

Frequently Asked Questions about Alivus Life Sciences Ltd

Alivus Life Sciences Ltd (ALIVUS) is currently trading at 1,102.70 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Alivus Life Sciences Limited, formerly Glenmark Life Sciences, specializes in developing, manufacturing, and marketing Active Pharmaceutical Ingredients (APIs) across various therapeutic segments. The company's Q3 FY26 revenue saw substantial growth of 14.4% QoQ, driven by recovery in the CDMO segment and robust demand in regulated markets such as Europe and Japan. Alivus has successfully expanded its capacity, notably in Dahej and Ankleshwar, aligning with its strategy of supporting sustained growth in its CDMO and API businesses. The company reported its highest ever EBITDA margin of 36.4% in Q3 FY26, supported by new product launches and favorable product mixes. Alivus is strategically focused on expanding its CDMO business, aiming for new project wins and leveraging operational efficiencies to sustain margin expansion.

Over the past 52 weeks, Alivus Life Sciences Ltd has traded between a low of ₹830.00 and a high of ₹1,193.30. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Alivus Life Sciences Ltd has a market capitalization of approximately 13,875.69. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Alivus Life Sciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 24.58 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 13,875.69 Cr, Alivus Life Sciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Alivus Life Sciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Alivus Life Sciences Ltd is 24.58. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Revenue from operations was ₹5,879.80 million and net profit (PAT) was ₹1,300.26 million in Q2FY26.

The 10,000 crore Biopharma Shakti scheme supports the domestic production of biologics and biosimilars, providing a strategic framework for Alivus to expand its advanced API and biopharma manufacturing capabilities.

Alivus Life Sciences Ltd

Stock Summary and Key Metrics

Investment Checklist

Investment Checklist

Overview

Financial Ratios

Technicals

Forecasts

Unlock more with professional

Peers

Price Chart Comparison